ANTI-CD19

Clinical trials for ANTI-CD19 explained in plain language.

Never miss a new study

Get alerted when new ANTI-CD19 trials appear

Sign up with your email to follow new studies for ANTI-CD19, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug budoprutug aims to boost platelets in ITP patients

Disease control Recruiting now

This study tests a new drug, budoprutug, in 24 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The main goal is to check safety and find the right dose, while also seeing if it helps raise platelet counts.…

Matched conditions: ANTI-CD19

Phase: PHASE1, PHASE2 • Sponsor: Climb Bio, Inc. • Aim: Disease control

Last updated May 22, 2026 13:51 UTC

ANTI-CD19

Get alerted when new ANTI-CD19 trials appear

New drug budoprutug aims to boost platelets in ITP patients